
US-based pharmaceutical company Eli Lilly has presented results from the third quarter of 2021, and in connection with the release, expectations for earnings per share have been adjusted.
Thus, the expected earnings per share (non-GAAP) for 2021 are now USD 7.95-8.05, up from the previous USD 7.8-8.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app